

All-India Institute of Medical Sciences
Ansari Nagar, New Delhi-29
(RESEARCH SECTION)

Ref. No. 12/Stores/Ped/SG/18-19/RS

Dated: 24.09.2018

Subject: Purchase of Filmarray System (Meningitis/encephalitis panel double multiplex PCR systems with consumables/accessories, Deptt. of Pediatrics, AIIMS on proprietary basis-Inventing Comments thereon.

To purchase the subject item from M/s bioMerieux India Pvt. Ltd. (Mfg. by M/s.Biomerieux S.A.France) on proprietary basis. The proposal submitted by M/s bioMerieux India Pvt. Ltd.and Performa Invoice are attached.

The above documents are being uploaded for open information to submit objections, comments, if any, from any manufacturer regarding proprietary nature of the equipment/item within issue of 15 days giving reference **No. 12/Stores/Ped./SG/18-19/St.** The comments should be received by office of Stores Officer(RS), Research Section at AIIMS on or before **10/10/2018 upto 12:00 p.m.**, failing which it will be presumed that any other vendor is having no comment to offer and case will be decided on merits.

STORES OFFICER (RS)

Encl: Related documents enclosed.

- 1. PAC Certificate enclosed.**
- 2. Performa Invoice**



PROFORMA INVOICE					
bioMérieux India Pvt. Ltd. 43A, Okhla Industrial Estate, Phase-III New Delhi - 110020 Tell :42098800		No. BMX/FA 2.0/18		Dated 17-Aug-18	
BILL TO		Ref No.		Dated	
To, The Director All India Institute Of Medical Sciences Ansari Nagar , New Delhi 110029		1) Purchase of Bio Fire FilmArray 2.0 System			
Ship To					
The Director All India Institute Of Medical Sciences Ansari Nagar , New Delhi 110029					
Sr No.	Description	Quoted Model	Qty (Nos.)	Unit Price (Rs.)	Total Price (Rs.)
1	Automated Bio Fire FilmArray 2.0 System	Bio Fire FilmArray 2.0	1	3,700,000	3,700,000
	Warranty - 05 yrs. from the date of installation				
	CAMC @4% of quoted price per year after the warranty period + GST as applicable				
	All software upgradation free of cost during warranty and CAMC period				
				GST 5@	185,000.0
	Total No. of Quantities (1)			Grand Total	3,885,000
Rupees Thirty Eight Lakhs Eighty Five Thousand only.					
All other terms & conditions as per above tender ref					
GST NO. 06AAACB4984F1ZQ					
Declaration We declare that this invoice shows the actual price of the goods described and that all particulars are true and correct					



For bioMérieux India Pvt. Ltd.

 Authorized Signatory

SUBJECT TO NEW DELHI JURISDICTION

ATTESTED

 NOTARY PUBLIC
 DELHI (INDIA)

20 AUG 2018

PROFORMA INVOICE		BIOMERIEUX		Dated	
bioMerieux India Pvt. Ltd. 43A, Okhla Industrial Estate, Phase-III New Delhi - 110020 Toll :42098800		BMX/IFAZ/0/18		17-Aug-18	
BILL TO		Ref No.		Dated	
To: The Director All India Institute Of Medical Science's Ansari Nagar , New Delhi 110029		1) Purchase of Bio Fire FilmArray 2.0 Testing Panel			
Ship To					
The Director All India Institute Of Medical Science's Ansari Nagar , New Delhi 110029					
Sr No.	Panel Description	Pack Size	Qty (Nos.)	One test price	Total kit Price (Rs.)
1	Meningitis & encephalitis ME panel/BCID Panel/GI Panel/RP panel	6Test each	1	12,500	75,000
	Prices for the all panel will remain same during 5 year Warranty period.				
	price for refresh / new panel will be same as quoted panel				
				GST 12@	9,000
Total No. of Quantities (1)				Grand Total	84,000
Rupees Eighty four Thousand only.					
All other terms & conditions as per above tender ref					
GST NO. 06AAACB4984F1ZQ					
Declaration					
We declare that this invoice shows the actual price of the goods described and that all particulars are true and correct					

For bioMerieux India Pvt. Ltd.

Authorized Signatory

SUBJECT TO NEW DELHI JURISDICTION



NOTARY PUBLIC
DELHI (INDIA)

20 AUG 2018



17th Aug, 2018

**Proprietary Article Certificate
AUTOMATED BIOFIRE FILM ARRAY SYSTEM**

This is to certify that **Automated BioFire Film Array system** is a proprietary product of Biofire Diagnostics a company owned by **Biomerieux S.A France** and is manufactured & marketed exclusive all over India by its wholly owned subsidiary **Biomerieux India Pvt Ltd**.

FilmArray system is intended for use in combination with assay specific reagent pouched to detect multiple nucleic acid targets contained in the clinical specimen.


The following **BioFire reagents/consumables** used in the above system are also proprietary of Biomerieux distributed and marketed in India by its wholly owned 100 % subsidiary **Biomerieux India Pvt Ltd** ,New Delhi and through its authorized set of distributors only

- FilmArray M/E Panel**
- FilmArray GI Panel**
- FilmArray BCID ID Panel**
- FilmArray RP Panel**

The above consumables are unique and can be used only in above system
The above futures are unique and there are no other manufacturers of above products in the world.

Yours Faithfully
For **Biomerieux India Pvt Ltd**

Authorized Signatory



ATTESTED

NOTARY PUBLIC
DELHI (INDIA)

20 AUG 2018



Date: 20/8/2018

TO WHOMSOEVER IT MAY CONCERN

This is to bring in your kind notice that according to USPTO Section 120 /121/365(c) Or 386 (c), patent term is considered 20 years from the date on which the application for the patent was filed in UNITED STATES (USA) or, PCT filing date. Patent No. US8394608B2 PCT patent application was filed on May 8th, 2006 under PCT application no. PCT/US2006/017665 and patent was granted Mar 12th, 2013. With reference to patent law this patent is valid till May 7th, 2026.

(Authorized Signatory)



ATTESTED

**NOTARY PUBLIC
DELHI (INDIA)**

20 AUG 2018



US008394608B2

(12) **United States Patent**
Ririe et al.

(10) Patent No.: **US 8,394,608 B2**
(45) Date of Patent: **Mar. 12, 2013**

(54) **SELF-CONTAINED BIOLOGICAL ANALYSIS**

(75) Inventors: **Kirk M. Ririe**, Salt Lake City, UT (US);
Michael R. Newwander, Hyde Park, UT (US); **Randy P. Rasmussen**, Salt Lake City, UT (US); **Mark Aaron Parfutz**, Salt Lake City, UT (US);
Stewart Benjamin Smith, Salt Lake City, UT (US); **David E. Jones**, Clearfield, UT (US); **Gary Clark Kessler**, Bountiful, UT (US)

(73) Assignee: **BioFire Diagnostics, Inc.**, Salt Lake City, UT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 728 days.

(21) Appl. No.: **11/913,120**

(22) PCT Filed: **May 8, 2006**

(86) PCT No.: **PCT/US2006/017665**

§ 371 (c)(1),
(2), (4) Date: **Sep. 16, 2009**

(87) PCT Pub. No.: **WO2006/121997**

PCT Pub. Date: **Nov. 16, 2006**

(65) **Prior Publication Data**

US 2010/0105029 A1 Apr. 29, 2010

Related U.S. Application Data

(60) Provisional application No. 60/679,052, filed on May 9, 2005.

(51) Int. Cl. **C12P 19/34** (2006.01)

(52) U.S. Cl. **435/91.2**

(58) Field of Classification Search None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,229,297 A	7/1993	Schnipelsky et al.	
5,620,869 A	4/1997	Woodward et al.	
5,863,502 A *	1/1999	Southgate et al.	422/417
5,876,924 A *	3/1999	Zhang et al.	435/5
6,100,084 A *	8/2000	Miles et al.	435/306.1
6,235,471 B1	5/2001	Knapp et al.	
6,605,451 B1 *	8/2003	Marmaro et al.	435/91.2
6,645,758 B1 *	11/2003	Schnipelsky et al.	435/287.2
6,964,862 B2 *	11/2005	Chen	435/91.2
2003/0008308 A1	1/2003	Engelberger et al.	
2004/0209331 A1 *	10/2004	Ririe	435/91.2

OTHER PUBLICATIONS

Yeh et al. (2004) J. of Hepatology 41: pp. 659-666.*
Taylor et al. (2001) Anal. Chem. vol. 73: pp. 492-496.*
Oster et al. (2001) Journal of Magnetism and Magnetic Materials 225: pp. 145-150.*
Findley et al., Automated closed-vessel system for in vitro diagnostics based on polymerase chain reaction (1993) pp. 1927-1933.


* cited by examiner

Primary Examiner — Teresa E Strzelecka
Assistant Examiner — Suchira Pande
(74) *Attorney, Agent, or Firm* — Maginot, Moore & Beck, LLP

(57) **ABSTRACT**

Devices, containers, and methods are provided for performing biological analysis in a closed environment. Illustrative biological analysis include nucleic acid amplification and detection and immuno-PCR.

24 Claims, 12 Drawing Sheets



- 2701-Patent Term
- 2702-2709 [Reserved]
- 2710-Term Extensions or Adjustments for Delays Within the USPTO Under 35 U.S.C. 154
- 2711-2719 [Reserved]
- 2720-Applications Filed Between June 8, 1995, and May 29, 2000
- 2721-2729 [Reserved]
- 2730-Applications Filed on or After May 29, 2000; Grounds for Adjustment
- 2731-Period of Adjustment
- 2732-Reduction of Period of Adjustment of Patent Term
- 2733-Patent Term Adjustment Determination
- 2734-Application for Patent Term Adjustment; Data Core Showing
- 2735-[Reserved]

2701 Patent Term [R-07.2015]

35 U.S.C. 154 Contents and term of patent; provisional rights.

(a) IN GENERAL.—

- (2) TERM.—Subject to the payment of fees under this title, such grant shall be for a term beginning on the date on which the patent issues and ending 20 years from the date on which the application for the patent was filed in the United States or, if the application contains a specific reference to an earlier filed application or applications under section 120, 121, 365(c), or 386(c) from the date on which the earliest such application was filed.
- (3) PRIORITY.—Priority under section 119, 365(a), 365(b), 386(a), or 386(b) shall not be taken into account in determining the term of a patent.

(c) CONTINUATION.—

- (1) DETERMINATION.—The term of a patent that is in force on or that results from an application filed before the date that is 6 months after the date of the enactment of the Uruguay Round Agreements Act shall be the greater of the 20-year term as provided in subsection (a), or 17 years from grant, subject to any terminal disclaimer.
- (2) REMEDIES.—The remedies of sections 283, 284, and 285 shall not apply to acts which —
 - (A) were commenced or for which substantial investment was made before the date that is 6 months after the date of the enactment of the Uruguay Round Agreements Act; and
 - (B) became infringing by reason of paragraph (1).
- (3) REMUNERATION.—The acts referred to in paragraph (2) may be continued only upon the payment of an equitable remuneration to the patentee that is determined in an action brought under chapter 28 and chapter 29 (other than those provisions excluded by paragraph (2)).